FDA approves Fiasp to treat diabetes in children

no and Nord announced today that the U.S. Food and Drug Administration has approved 100 u/ ml of Fiasp (mendon insulin injection) as an insulin option for new meals for children with diabetes. Fiasp is the first and only quick-acting drug to not have a recommended pre-meal insulin dose before meals. Fiasp is now available in three different dose options for children and adults: multiple injections per day, continuous off-skin insulin infusion pumps, and intravenous infusion under the supervision of a healthcare professional.
Diabetes is one of the most common chronic diseases in childhood, with nearly 18,000 new cases of type 1 diabetes each year. Managing diabetes can be a challenge for parents and caregivers because it is difficult to know exactly how much or how fast your child is eating, making insulin administration difficult at mealtimes. Regular quick-acting insulin must be taken before meals, which requires some speculation to be taken correctly, and children with diabetes may not be able to get adequate blood sugar control.
"As a parent of a son with type 1 diabetes, I knew firsthand how to solve the inevitable problem of elevated blood sugar at meal time," said Todd Hobbs, vice president and chief medical officer of Noor Nord. Children can be unpredictable, and choosing fast-acting insulin like Fiasp, which doesn't require pre-meal medication, is a welcome development for the diabetic community. Thethe FDA's review of data from the onset 7 clinical trial, which confirmed Fiasp's effectiveness and safety in children. （cyy123.com）